Leuconostoc Citrum Composition for Multi-Cause Intestinal Damage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compositions do not effectively address intestinal damage caused by inflammatory bowel disease, non-alcoholic steatohepatitis, and chemotherapy, and there is a lack of therapeutic or preventive effects using a Leuconostoc citreum strain as an active ingredient.
Innovation Solution
A pharmaceutical, food, or feed composition comprising a Leuconostoc citreum strain or its culture as an active ingredient, which can be administered orally or parenterally, to prevent or treat intestinal damage, including intestinal damage caused by inflammatory bowel disease, non-alcoholic steatohepatitis, and chemotherapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional probiotic compositions are used, then general intestinal health may be maintained, but intestinal damage caused by inflammatory bowel disease, non-alcoholic steatohepatitis, and chemotherapy cannot be effectively prevented or treated
Solution Approach 1:
The patent changes the specific probiotic strain parameter from conventional strains to Leuconostoc citreum strain, which has been specifically identified as having superior effectiveness in treating multiple types of intestinal damage including inflammatory bowel disease, non-alcoholic steatohepatitis, and chemotherapy-induced damage, while maintaining safety and tolerability
Solution Approach 2:
The Leuconostoc citreum strain demonstrates multi-functionality by being effective across multiple types of intestinal damage conditions simultaneously, including inflammatory bowel disease, non-alcoholic steatohepatitis, and chemotherapy-induced intestinal damage, thereby expanding the compositional applicability beyond single-condition treatments
2Reliability
If existing probiotic compositions are used, then some intestinal health benefits are achieved, but toxicity and side effects remain a concern
Solution Approach 1:
The patent employs Leuconostoc citreum, a probiotic strain with a well-established safety profile and short history of use, avoiding the need for long-term commitment to potentially harmful substances. The strain has demonstrated therapeutic effectiveness while maintaining low toxicity and side effect profiles, making it a safe short-term intervention option
Solution Approach 2:
Leuconostoc citreum acts as an intermediary substance that mediates between the harmful effects of intestinal damage conditions and the host's immune system, providing therapeutic benefits while minimizing direct toxicity and adverse reactions through its modulatory properties
3Reliability
If the Leuconostoc citreum strain is introduced as a new active ingredient, then treatment effectiveness for intestinal damage is improved, but formulation and regulatory challenges increase
Solution Approach 1:
The patent performs preliminary characterization and safety assessment of the Leuconostoc citreum strain before formulation, including evaluation of its probiotic properties, safety profile, and mechanisms of action. This preliminary work establishes a foundation for regulatory compliance and manufacturing standardization, reducing future development challenges
Solution Approach 2:
The patent optimizes formulation parameters such as strain concentration, delivery method, and combination with other agents to maximize the preventive and therapeutic effects of Leuconostoc citreum while maintaining manufacturability and regulatory compliance, balancing efficacy with production feasibility
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The Leuconostoc citreum strain composition effectively prevents or treats intestinal damage by restoring intestinal function and maintaining intestinal health, as demonstrated by gene expression level restoration in enterocytes and animal models.
Implementation Method 1
leveraging its probiotic properties to regulate the intestinal microbiota and enhance immune function
Implementation Method 2
restoring gene expression levels of tight junction proteins, such as ZO1 and Occludin, thereby improving intestinal barrier function
Data Source
AI summary
The present invention relates to a composition comprising a Leuconostoc citreum strain or a culture thereof as an active ingredient for preventing, improving or treating intestinal damage, specifically intestinal damage caused by inflammatory bowel disease, non-alcoholic steatohepatitis or chemotherapy.According to the present invention, since the composition exhibits excellent preventive and therapeutic effects on various intestinal damages such as inflammatory bowel disease, non-alcoholic steatohepatitis, and chemotherapy, the composition can be usefully used as a composition for the treatment, prevention or improvement of human or animal intestinal damage.